Onkure Therapeutics, Inc. current report, 02 March 2022

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Reneo Pharmaceuticals, Inc. (trading symbol: RPHM) on March 2, 2022. The filing discloses executive appointments and associated compensatory arrangements effective immediately and March 31, 2022.

Key Financial Metrics

The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel changes and compensation adjustments.

Material Changes

The Company announced two significant executive appointments with corresponding compensation increases:

  • Michael P. Cruse: Appointed Chief Operating Officer (COO) effective March 2, 2022.
    • Base salary increased from $350,000 to $400,000 annually.
    • Discretionary bonus target increased from 35% to 40%.
    • Granted an option to purchase 25,000 shares of common stock, vesting over 48 months.
    • Severance benefits for change-in-control scenarios increased from 9 to 12 months of base salary and COBRA premiums.
  • Jennifer P. Lam: Appointed Principal Financial and Accounting Officer (CFO) effective March 31, 2022.
    • Base salary increased from $309,000 to $320,000 annually.
    • Granted an option to purchase 10,000 shares of common stock, vesting over 48 months.

Guidance, Outlook, and Risks

The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It notes that neither executive has family relationships with directors or officers and has no material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.

Investor Verification Checklist

  • Verify the vesting schedule and exercise price of the 25,000 options granted to Michael P. Cruse and the 10,000 options granted to Jennifer P. Lam.
  • Confirm the specific definitions of "cause," "resignation for good reason," and "change in control" within the Company's Severance Plan to understand the 12-month severance trigger.
  • Review the Company's most recent 10-K or 10-Q for current cash position to assess the impact of increased executive compensation on liquidity.